公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
1997 | A neuro-control system for the knee joint position control with quadriceps stimulation | Chang G.-C.; JER-JUNN LUH ; Liao G.-D.; Lai J.-S.; Cheng C.-K.; Kuo B.-L.; Kuo T.-S. | IEEE Transactions on Rehabilitation Engineering | 103 | 0 | |
2006 | A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma | Tsai M.-F.; Wang C.-C.; Chang G.-C.; Chen C.-Y.; Chen H.-Y.; Cheng C.-L.; Yang Y.-P.; Wu C.-Y.; Shih F.-Y.; Liu C.-C.; Lin H.-P.; Jou Y.-S.; Lin S.-C.; CHUNG-WU LIN ; WEI J. CHEN ; Chan W.-K.; Chen J.J.W.; PAN-CHYR YANG | Journal of the National Cancer Institute | 101 | 98 | |
2020 | Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan | Chen Y.-M.; CHIH-HSIN YANG ; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO ; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU | Journal of the Formosan Medical Association | 8 | 5 | |
2022 | An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study | Su P.-L.; Chang G.-C.; Hsiao S.-H.; Hsia T.-C.; Lin M.-C.; Lin M.-H.; JIN-YUAN SHIH ; Yang C.-T.; Yang S.-H.; Chen Y.-M. | JTO Clinical and Research Reports | 2 | 0 | |
2016 | Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma | Su T.-J.; Ku W.-H.; Chen H.-Y.; Hsu Y.-C.; Hong Q.-S.; Chang G.-C.; SUNG-LIANG YU ; Chen J.J.W. | American Journal of Cancer Research | 22 | | |
2016 | Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition | Lin S.-Y.; Lee Y.-X.; SUNG-LIANG YU ; Chang G.-C.; Chen J.J.W. | Oncotarget | 7 | 7 | |
2009 | A polymorphism in the APE1 gene promoter is associated with lung cancer risk | Lo Y.-L.; Jou Y.-S.; Hsiao C.-F.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; KUAN-YU CHEN ; Chen Y.-M.; Huang M.-S.; Chi Y.H.; Chen C.-J.; Hsiung C.A. | Cancer Epidemiology Biomarkers and Prevention | 74 | 71 | |
2011 | Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers | Lo Y.-L.; Hsiao C.-F.; Jou Y.-S.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; KUAN-YU CHEN ; Chen Y.-M.; Huang M.-S.; Hsieh W.-S.; Chen C.-J.; Hsiung C.A. | Lung Cancer | 53 | 50 | |
2017 | Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study | Chang G.-C.; Tseng C.-H.; Hsu K.-H.; CHONG-JEN YU ; Yang C.-T.; Chen K.-C.; Yang T.-Y.; Tseng J.-S.; Liu C.-Y.; WEI-YU LIAO ; Hsia T.-C.; Tu C.-Y.; Lin M.-C.; Tsai Y.-H.; Hsieh M.-J.; Wu W.-S.; Chen Y.-M. | Lung Cancer | 22 | 18 | |
2006 | Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients | Chang G.-C.; Tsai C.-M.; Chen K.-C.; CHONG-JEN YU ; JIN-YUAN SHIH ; Yang T.-Y.; Lin C.-P.; Hsu J.-Y.; Chiu C.-H.; Perng R.-P.; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
2016 | Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients | Huang Y.-H.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; KANG-YI SU ; Chen H.-Y.; Chang C.-S.; Chen J.J.W.; SUNG-LIANG YU ; HUEI-WEN CHEN ; Yang T.-Y.; Chang G.-C. | Journal of Thoracic Disease | 2 | 2 | |
2012 | Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer | KANG-YI SU ; Chen H.-Y.; Li K.-C.; Kuo M.-L.; CHIH-HSIN YANG ; Chan W.-K.; Ho B.-C.; Chang G.-C.; JIN-YUAN SHIH ; SUNG-LIANG YU ; PAN-CHYR YANG | Journal of Clinical Oncology | 464 | 428 | |
2015 | R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability | Chen H.-Y.; SUNG-LIANG YU ; Ho B.-C.; KANG-YI SU ; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; CHONG-JEN YU ; KUAN-YU CHEN ; Tsai Y.-H.; Su W.-C.; HUEI-WEN CHEN ; Chen J.J.W.; Chen C.-J.; Chang G.-C.; PAN-CHYR YANG ; Li K.-C. | Journal of Clinical Oncology | 76 | 71 | |
2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 397 | 341 | |
1996 | Real-time implementation of electromyogram pattern recognition as a control command of man-machine interface | Chang G.-C.; Kang W.-J.; JER-JUNN LUH ; Cheng C.-K.; Lai J.-S.; Chen J.-J.J.; Kuo T.-S. | Medical Engineering and Physics | 60 | 46 | |
2019 | The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan | Tseng C.-H.; Tsuang B.-J.; CHUN-JU CHIANG ; Ku K.-C.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; SUNG-LIANG YU ; WEN-CHUNG LEE ; Liu T.-W.; CHANG-CHUAN CHAN ; Chang G.-C. | Journal of Thoracic Oncology | 115 | 106 | |
2007 | Revisit of 1997 TNM staging system - Survival analysis of 1112 lung cancer patients in Taiwan | Perng R.-P.; Chen C.-Y.; Chang G.-C.; Hsia T.-C.; Hsu N.-Y.; Tsai Y.-H.; Tsai C.-M.; CHIH-HSIN YANG ; Chen Y.-M.; CHONG-JEN YU ; Lee J.-J.; Hsu H.-S.; Yu C.-T.; Kao E.-L.; Chiu C.-H. | Japanese Journal of Clinical Oncology | 12 | 7 | |
2015 | Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways | Lai Y.-H.; Chen M.-H.; Lin S.-Y.; Lin S.-Y.; Wong Y.-H.; SUNG-LIANG YU ; HUEI-WEN CHEN ; CHIH-HSIN YANG ; Chang G.-C.; Chen J.J.W. | Oncotarget | 10 | 8 | |
2013 | Risk factors for primary lung cancer among never smokers by gender in a matched case-control study | Lo Y.-L.; Hsiao C.-F.; Chang G.-C.; Tsai Y.-H.; Huang M.-S.; Su W.-C.; Chen Y.-M.; Hsin C.-W.; Chang C.-H.; PAN-CHYR YANG ; Chen C.-J.; Hsiung C.A. | Cancer Causes and Control | 53 | 43 | |
2020 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | CHIH-HSIN YANG ; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. | Journal of Thoracic Oncology | 87 | 75 | |